248 related articles for article (PubMed ID: 33913652)
1. Polypill in Persons without Cardiovascular Disease.
Cainzos-Achirica M
N Engl J Med; 2021 Apr; 384(17):1675-1676. PubMed ID: 33913652
[No Abstract] [Full Text] [Related]
2. Polypill in Persons without Cardiovascular Disease.
Wald N; Wald D; Law M
N Engl J Med; 2021 Apr; 384(17):1675. PubMed ID: 33913651
[No Abstract] [Full Text] [Related]
3. Polypill in Persons without Cardiovascular Disease.
Messerli FH; Brguljan J; Bangalore S
N Engl J Med; 2021 Apr; 384(17):1674-1675. PubMed ID: 33913650
[No Abstract] [Full Text] [Related]
4. Polypill in Persons without Cardiovascular Disease.
Alam A; Carey SA; Hall SA
N Engl J Med; 2021 Apr; 384(17):1674. PubMed ID: 33913649
[No Abstract] [Full Text] [Related]
5. Polypill in Persons without Cardiovascular Disease.
Gallieni M; Paik JM; Fiorina P
N Engl J Med; 2021 Apr; 384(17):1673-1674. PubMed ID: 33913648
[No Abstract] [Full Text] [Related]
6. Polypill with or without Aspirin in Persons without Cardiovascular Disease.
Yusuf S; Joseph P; Dans A; Gao P; Teo K; Xavier D; López-Jaramillo P; Yusoff K; Santoso A; Gamra H; Talukder S; Christou C; Girish P; Yeates K; Xavier F; Dagenais G; Rocha C; McCready T; Tyrwhitt J; Bosch J; Pais P;
N Engl J Med; 2021 Jan; 384(3):216-228. PubMed ID: 33186492
[TBL] [Abstract][Full Text] [Related]
7. Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk.
Lafeber M; Spiering W; Visseren FL; Grobbee DE; Bots ML; Stanton A; Patel A; Prabhakaran D; Webster R; Thom S; Rodgers A;
Eur J Prev Cardiol; 2017 Jun; 24(9):951-961. PubMed ID: 28436727
[TBL] [Abstract][Full Text] [Related]
8. The evening versus morning polypill utilization study: the TEMPUS rationale and design.
Lafeber M; Grobbee DE; Bots ML; Thom S; Webster R; Rodgers A; Visseren FL; Spiering W
Eur J Prev Cardiol; 2014 Apr; 21(4):425-33. PubMed ID: 23382539
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of Polypill for Prevention of Cardiovascular Disease (PolyPars): Protocol of a Randomized Controlled Trial.
Malekzadeh F; Gandomkar A; Malekzadeh Z; Poustchi H; Moghadami M; Fattahi MR; Moini M; Anushiravani A; Mortazavi R; Sadeghi Boogar S; Mohammadkarimi V; Abtahi F; Merat S; Sepanlou SG; Malekzadeh R
Arch Iran Med; 2020 Aug; 23(8):548-556. PubMed ID: 32894967
[TBL] [Abstract][Full Text] [Related]
10. Polypill in Persons without Cardiovascular Disease. Reply.
Yusuf S; Joseph P; Pais P
N Engl J Med; 2021 Apr; 384(17):1676-1677. PubMed ID: 33913653
[No Abstract] [Full Text] [Related]
11. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk.
Patel A; Cass A; Peiris D; Usherwood T; Brown A; Jan S; Neal B; Hillis GS; Rafter N; Tonkin A; Webster R; Billot L; Bompoint S; Burch C; Burke H; Hayman N; Molanus B; Reid CM; Shiel L; Togni S; Rodgers A;
Eur J Prev Cardiol; 2015 Jul; 22(7):920-30. PubMed ID: 24676715
[TBL] [Abstract][Full Text] [Related]
12. A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke.
Carey KM; Comee MR; Donovan JL; Kanaan AO
Ann Pharmacother; 2012 May; 46(5):688-95. PubMed ID: 22570437
[TBL] [Abstract][Full Text] [Related]
13. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
; Yusuf S; Pais P; Afzal R; Xavier D; Teo K; Eikelboom J; Sigamani A; Mohan V; Gupta R; Thomas N
Lancet; 2009 Apr; 373(9672):1341-51. PubMed ID: 19339045
[TBL] [Abstract][Full Text] [Related]
14. Estimated cardiovascular relative risk reduction from fixed-dose combination pill (polypill) treatment in a wide range of patients with a moderate risk of cardiovascular disease.
Lafeber M; Webster R; Visseren FLj; Bots ML; Grobbee DE; Spiering W; Rodgers A;
Eur J Prev Cardiol; 2016 Aug; 23(12):1289-97. PubMed ID: 26743587
[TBL] [Abstract][Full Text] [Related]
15. Predicting the impact of polypill use in a metabolic syndrome population: an effectiveness and cost-effectiveness analysis.
Zomer E; Owen A; Magliano DJ; Ademi Z; Reid CM; Liew D
Am J Cardiovasc Drugs; 2013 Apr; 13(2):121-8. PubMed ID: 23532687
[TBL] [Abstract][Full Text] [Related]
16. Embracing the polypill as a cardiovascular therapeutic: is this the best strategy?
Franczyk B; Gluba-Brzózka A; Jurkiewicz Ł; Penson P; Banach M; Rysz J
Expert Opin Pharmacother; 2018 Dec; 19(17):1857-1865. PubMed ID: 30295098
[TBL] [Abstract][Full Text] [Related]
17. [The polypill: optimal strategy for reduction of cardiovascular disease].
Nathoe HM; Doevendans PA
Ned Tijdschr Geneeskd; 2005 Jul; 149(31):1740. PubMed ID: 16114290
[TBL] [Abstract][Full Text] [Related]
18. Polypill for prevention of cardiovascular diseases with focus on non-alcoholic steatohepatitis: the PolyIran-Liver trial.
Merat S; Jafari E; Radmard AR; Khoshnia M; Sharafkhah M; Nateghi Baygi A; Marshall T; Shiravi Khuzani A; Cheng KK; Poustchi H; Malekzadeh R
Eur Heart J; 2022 Jun; 43(21):2023-2033. PubMed ID: 35048107
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of the polypill versus risk assessment for prevention of cardiovascular disease.
Ferket BS; Hunink MG; Khanji M; Agarwal I; Fleischmann KE; Petersen SE
Heart; 2017 Apr; 103(7):483-491. PubMed ID: 28077465
[TBL] [Abstract][Full Text] [Related]
20. Use of a Multidrug Pill In Reducing cardiovascular Events (UMPIRE): rationale and design of a randomised controlled trial of a cardiovascular preventive polypill-based strategy in India and Europe.
Thom S; Field J; Poulter N; Patel A; Prabhakaran D; Stanton A; Grobbee DE; Bots ML; Reddy KS; Cidambi R; Rodgers A
Eur J Prev Cardiol; 2014 Feb; 21(2):252-61. PubMed ID: 23038750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
